BioCity firms forge JV to offer integrated drug discovery
Nottingham-based XenoGesis and Glasgow’s BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.
The firm says the move will allow them to offer tailored solutions for clients and a more personalised service.
Richard Weaver, managing director of XenoGesis, said: “Our two businesses are closely aligned and offer great synergies for our clients, to provide a quick and effective route to drug discovery. There are very few organisations that genuinely can provide leading chemistry, biology and DMPK expertise collectively, with a track record of producing a series of viable candidates. Together we will provide a seamless relationship that allows for iterative drug design programmes, whilst reducing costs, improving timelines and increasing success rates for our clients.”
Chief executive of BioAscent, Paul Smith, added: “BioAscent has recently launched its integrated drug discovery services with a truly exceptional team of medicinal chemists and biologists, building on our established capabilities in compound management and our in-house Compound Cloud library. This strategic alliance with XenoGesis means we can also offer specialist DMPK capabilities and assay evaluation to identify – at the earliest possible stage in the drug discovery process – those compounds that a client can take forward. Together we seek to not just provide our clients with data, but also iterative feedback and advice, right from the start.”
XenoGesis and BioAscent have both received investment from BioCity Group and are based at BioCity Group sites in Nottingham and Glasgow.